Hillcon Company is a technology enterprise dedicated to the research and development, production, and clinical application of blood purification equipment. Since its establishment in 2009, Hillcon has been focused on innovation in the field of blood adsorption technology. The company's products include resin flowmeters, activated carbon resin flowmeters, bilirubin adsorption columns, low-density lipoprotein adsorption columns, endotoxin adsorption columns, tumor factor adsorption columns, and various specific adsorption columns such as immunoglobulin A. Hillcon collaborates with multiple research institutions such as the Institute of Molecular Biology at Nankai University, the School of Environment and Life Science at Dalian University of Technology, Chongqing Medical University, and the School of Biomedical Engineering at Chongqing University. The company has a team of experienced professionals, with all management personnel holding a bachelor's degree or higher. Specifically, 6% hold senior titles, 20% hold intermediate titles, and several hold junior titles, forming a highly qualified, high-level, and youthful team. Hillcon is committed to developing blood flowmeters with international advanced standards. It possesses complete core technologies for the production and manufacturing of blood flowmeters, including raw material synthesis, specialized equipment manufacturing, and tank design, all of which are fully owned by the company. The company has applied for 18 national patents, filling some technical gaps domestically and achieving the import replacement of blood flowmeters. This has enhanced China's international competitiveness in this industry and marked our alignment with global technological trends in the field of blood purification equipment. Hillcon has clear property rights, sound corporate governance, a complete organizational structure, and well-established management systems. The company has already passed ISO13485 quality system certification. Hillcon received its first round of venture capital in 2010 and subsequently obtained investments from two renowned domestic venture capital companies in 2012, indicating that its products and technology have been recognized and affirmed by prominent investment institutions. Hillcon's corporate spirit is "Brave to advance, brave to strive, brave to innovate, brave to climb, and endless pursuit." The company continues to make breakthroughs and aims to enter the top three in China's blood flowmeter sector within 8 to 10 years.